Watch ABT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
52
WATCH · insiders 25, shorts 78
Insiders, 90 days
−$46.2M
net selling · 0 buys, 3 sells
Congress, 90 days
3 / 4
buys / sells · latest disclosed Aug 18
Big money
4 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $188.7BP/E 30.3DIV YIELD 2.25%FCF YIELD 3.91%REV TTM $45.1B +6.6%NET INCOME $6.3B −53.5%NET DEBT $6.1B52W 82.56 – 136.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | $11.2B | +7.8% | 56.2% | $1.3B | $1.1B | −18.7% | 0.61 | $1.3B | $399M | $916M | Apr 29 |
| Q4 2025 · Dec 31derived | $11.5B | +4.4% | 57.0% | $2.3B | $1.8B | −80.8% | 1.02 | $3.3B | $689M | $2.6B | Feb 20 |
| Q3 2025 · Sep 30 | $11.4B | +6.9% | 55.4% | $2.1B | $1.6B | −0.1% | 0.94 | $2.8B | $496M | $2.3B | Oct 29 |
| Q2 2025 · Jun 30 | $11.1B | +7.4% | 56.4% | $2.1B | $1.8B | +36.6% | 1.01 | $2B | $502M | $1.5B | Jul 30 |
| Q1 2025 · Mar 31 | $10.4B | +4.0% | 56.9% | $1.7B | $1.3B | +8.2% | 0.76 | $1.4B | $484M | $933M | Apr 29 |
| Q4 2024 · Dec 31derived | $11B | +7.2% | 55.0% | $1.9B | $9.2B | +479.0% | 5.26 | $2.9B | $720M | $2.1B | Feb 20 |
| Q3 2024 · Sep 30 | $10.6B | +4.9% | 55.8% | $1.9B | $1.6B | +14.6% | 0.94 | $2.7B | $556M | $2.1B | Oct 29 |
| Q2 2024 · Jun 30 | $10.4B | +4.0% | 55.6% | $1.7B | $1.3B | −5.3% | 0.74 | $2B | $533M | $1.4B | Jul 30 |
| Q1 2024 · Mar 31 | $10B | — | 55.2% | $1.4B | $1.2B | — | 0.70 | $1B | $398M | $627M | Apr 30 |
| Q4 2023 · Dec 31derived | $10.2B | — | 55.5% | $1.8B | $1.6B | — | 0.91 | $3B | $755M | $2.3B | Feb 20 |
| Q3 2023 · Sep 30 | $10.1B | — | 54.6% | $1.6B | $1.4B | — | 0.82 | $1.9B | $560M | $1.3B | Oct 31 |
| Q2 2023 · Jun 30 | $10B | — | 55.1% | $1.5B | $1.4B | — | 0.78 | $1.2B | $507M | $696M | Jul 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $44.3B | 56.4% | $8.1B | $6.5B | 14.7% | 3.72 | $9.6B | $2.2B | $7.4B | $893M | $4.1B |
| FY2024 · to Dec 31 | $42B | 55.4% | $6.8B | $13.4B | 31.9% | 7.64 | $8.6B | $2.2B | $6.4B | $1.3B | $3.8B |
| FY2023 · to Dec 31 | $40.1B | 55.2% | $6.5B | $5.7B | 14.3% | 3.26 | $7.3B | $2.2B | $5.1B | $1.2B | $3.6B |
| FY2022 · to Dec 31 | $43.7B | 56.1% | $8.4B | $6.9B | 15.9% | 3.91 | $9.6B | $1.8B | $7.8B | $3.8B | $3.3B |
| FY2021 · to Dec 31 | $43.1B | 57.0% | $8.4B | $7.1B | 16.4% | 3.94 | $10.5B | $1.9B | $8.6B | $2.3B | $3.2B |
| FY2020 · to Dec 31 | $34.6B | 56.6% | $5.4B | $4.5B | 13.0% | 2.50 | $7.9B | $2.2B | $5.7B | $403M | $2.6B |
Every number comes from ABBOTT LABORATORIES's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.